Your browser doesn't support javascript.
loading
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
Smith, Matthew R; Thomas, Shibu; Gormley, Michael; Chowdhury, Simon; Olmos, David; Oudard, Stéphane; Feng, Felix Y; Rajpurohit, Yashoda; Urtishak, Karen; Ricci, Deborah S; Rooney, Brendan; Lopez-Gitlitz, Angela; Yu, Margaret; Wyatt, Alexander W; Li, Mark; Attard, Gerhardt; Small, Eric J.
Afiliación
  • Smith MR; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts. MRSMITH@mgh.harvard.edu.
  • Thomas S; Janssen Research & Development, Spring House, Pennsylvania.
  • Gormley M; Janssen Research & Development, Spring House, Pennsylvania.
  • Chowdhury S; Guy's, King's and St. Thomas' Hospitals, Great Maze Pond, London, United Kingdom.
  • Olmos D; Spanish National Cancer Research Center (CNIO), and Hospital Universitario Virgen de la Victoria y Regional de Málaga, Madrid, Spain.
  • Oudard S; Oncology Department, Georges Pompidou Hospital, University of Paris, Paris, France.
  • Feng FY; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Rajpurohit Y; Janssen Research & Development, Spring House, Pennsylvania.
  • Urtishak K; Janssen Research & Development, Spring House, Pennsylvania.
  • Ricci DS; Janssen Research & Development, Spring House, Pennsylvania.
  • Rooney B; Janssen Research & Development, High Wycombe, United Kingdom.
  • Lopez-Gitlitz A; Janssen Research & Development, Los Angeles, California.
  • Yu M; Janssen Research & Development, Los Angeles, California.
  • Wyatt AW; The University of British Columbia, Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • Li M; Resolution Bioscience, Kirkland, Washington.
  • Attard G; University College London Cancer Institute, London, United Kingdom.
  • Small EJ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Clin Cancer Res ; 27(16): 4539-4548, 2021 08 15.
Article en En | MEDLINE | ID: mdl-34112710
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tiohidantoínas / Biomarcadores de Tumor / Neoplasias de la Próstata Resistentes a la Castración / Antagonistas de Andrógenos Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tiohidantoínas / Biomarcadores de Tumor / Neoplasias de la Próstata Resistentes a la Castración / Antagonistas de Andrógenos Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article